Compare ANVS & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANVS | VNRX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 31.9M |
| IPO Year | 2019 | 2012 |
| Metric | ANVS | VNRX |
|---|---|---|
| Price | $2.50 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.50 | $2.50 |
| AVG Volume (30 Days) | 306.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $1.11 | $0.17 |
| 52 Week High | $5.50 | $0.94 |
| Indicator | ANVS | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 42.62 |
| Support Level | $2.27 | $0.17 |
| Resistance Level | $2.63 | $0.27 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 21.54 | 36.63 |
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.